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 Background: Oral anticoagulants (OACs) such as warfarin and non-VKA oral anticoagulants (NOACs) have been recommended 
for patients with atrial fibrillation (AF) who are at risk for stroke. Whether NOACs have a higher persistence 
than warfarin is still unclear. This is especially true in China.
 Material/Methods: Data from a large hospital-based cohort in China (China-AF Registry) from 2011 to 2017 were used for this 
study. Non-valvular AF patients with newly initiated OACs were included. A time-to-event approach was used 
to analyze patient persistence. The survival distributions of persistence were compared using the log-rank test. 
A multivariable Cox regression model was used to explore predictors of warfarin and NOACs non-persistence.
 Results: Patients with newly initiated warfarin (n=4845) or NOACs (n=854) were included in this study. Persistence rates 
at 1, 2, and 3 years were 93.2%, 89.4%, and 87.2% in the warfarin group and 88.8%, 84.3%, and 81.3% in the 
NOAC group respectively. Non-persistence was significantly higher with NOACs than with warfarin. On multi-
variate analysis, age <75 years old, outpatient clinic visits, asymptomatic AF, paroxysmal AF, duration of AF <3 
years, history of peptic ulcer, and no previous TIA, stroke or thromboembolism were strong predictors of war-
farin non-persistence, while in the NOACs group, age <75 years old, outpatient clinic visits, lower education 
status and no history of congestive heart failure were predictors.
 Conclusions: Treatment persistence of NOACs was lower than that of warfarin among Chinese patients with AF. Patients 
with characteristics of non-persistence predictors need special attention to maintain their therapy.
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Background
Atrial fibrillation (AF) is the most common sustained arrhyth-
mia worldwide and is an important risk factor for ischemic 
stroke, and it is associated with high mortality and morbidity, 
and considerable medical costs [1]. Therefore, stroke preven-
tion is central to the management of AF. Oral anticoagulants 
(OACs) decrease the risk of thromboembolic events and mor-
tality in AF patients and are recommended for all AF patients 
at risk of stroke [2].
Optimal stroke prevention with OACs in AF patients depends 
on medication adherence, defined as the accurate intake of 
medications based on the dose, frequency, and schedule pre-
scribed [3]. Medication persistence to OACs, defined as the du-
ration of time from the initiation to discontinuation of therapy, 
is also widely adopted metrics to evaluate medical therapy [4]. 
Non-persistence to OACs is a major obstacle to stroke preven-
tion in AF [5–7].
The OACs include vitamin K antagonists (VKAs) such as war-
farin, and non-VKA oral anticoagulants (NOACs) such as dabi-
gatran, rivaroxaban, apixaban, and edoxaban. The most com-
monly used NOACs in China are dabigatran and rivaroxaban. 
Before NOACs were introduced, VKA warfarin was the standard 
anticoagulant therapy for patients with AF [8–10]. NOACs have 
been shown to be non-inferior to warfarin in terms of efficacy 
in stroke prevention, with a lower risk of major bleeding, with 
even better efficacy and safety in Asians compared to non-
Asians [11]. NOACs also have the advantage of not needing 
routine monitoring and dose-adjustment, due to limited food-
drug and drug-drug interactions. While some studies have 
shown that patients taking NOACs generally have higher per-
sistence than patients taking VKAs [12], other studies have 
shown the opposite [13,14]. No treatment persistence data 
exist in Chinese AF populations.
The purpose of this study was to investigate and compare ther-
apeutic persistence of warfarin and NOACs and explore factors 
associated with non-persistence to warfarin and NOACs ther-
apy in Chinese AF patients, using data of a large, prospective 
hospital-based registry cohort, the China AF Registry.
Material and Methods
Study population and data collection
The China-AF Registry enrolled AF patients in routine clin-
ical practice from 31 tertiary and non-tertiary hospitals in 
Beijing [15]. Eligible patients were recruited from outpatient 
clinics and in-hospital wards and all patients signed informed 
consent to participate. From August 2011 to December 2017, 
a total of 19 515 AF patients were recruited. Information on 
baseline characteristics included age, gender, body mass index 
(BMI), smoking status, alcohol consumption, education status, 
health insurance coverage, AF type, history of congestive heart 
failure, hypertension, diabetes, previous stroke/transient isch-
emic attack (TIA)/thromboembolism, prior bleeding events, pep-
tic ulcer, use of antiplatelet drugs, CHA2DS2-VASc score, and 
duration of AF were recorded upon patient enrolment.
The CHA2DS2-VASc score [16] was calculated by assigning 1 point 
for age between 65 and 74 years, a history of hypertension, 
diabetes, congestive heart failure, vascular disease, and fe-
male sex and 2 points for a history of stroke/TIA/thromboem-
bolism and age ³75 years. All definitions were consistent with 
the American College of Cardiology/American Heart Association 
recommendations for establishing an AF database [17].
A flowchart of patient-selection for the current analysis is 
shown in Figure 1. New initiation was defined as no OACs us-
age at the last time of follow-up while reported to be on the 
OAC therapy at the index follow-up. Exclusion criteria were as 
follows: age <18 years; follow-up time <6 months; with val-
vular AF (presence of mitral stenosis or mechanical valve im-
plantation); and those undergoing AF radiofrequency ablation.
Patients were categorized into a warfarin group and a NOACs 
group depending on the initial OACs. Patients who initiated 
warfarin and then switched to NOACs during follow-up were 
History of atrial fibrillation and newly-initiaded receiving warfarin or 
NOAC between August 1, 2011, and December 31, 2017 (N=16081)
Patients with non-valvular atrial fibrillation newly initiated warfarin or
NOAC (N=5775)
Age <18 years old, n=5 Underwent AF radiofrequency
ablation, n=9395
Initial warfarin use, n=5048
Crossover, n=203
Initial NOAC use, n=930
Crossover, n=76
NOAC group, n=854Warfarin group, n=4845
Initial NOAC use, n=727
History of valvular disease or
valvular surgery, n=355 Follow-up time less than six
months, n=551
Figure 1. Patients selection flowchart.
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allocated into the NOACs group and the initiation time was 
calculated from the time of switching. Patients who initiated 
NOAC and switched to warfarin during follow-up were ex-
cluded from the analysis as the number of these patients was 
small and therefore the impact would be minimal. Finally, 5699 
patients (4845 in the warfarin group and 854 in the NOACs 
group) were included.
Each patient was followed through outpatient interview or tele-
phone interview by trained nurse practitioners every 6 months 
after enrollment during a follow-up period of 3 years as NOACs 
were available in China 3 years ago. At follow-up intervals, 
medical conditions, serious adverse events (including bleeding 
complications), adverse drug reactions, and the date of discon-
tinuation of warfarin or NOACs were recorded. All data were 
entered into an electronic data collection platform.
Ethics
The project has been reviewed by the Beijing Anzhen Hospital 
Ethics Committee (No: D11110700300000) on June 10, 2011.
Definitions
Therapy persistence was defined as the duration of time 
from initiation to discontinuation of therapy. Initiation of 
therapy was defined as the index date for the first dose of 
the drug. Discontinuation was determined by self-reported 
cessation of warfarin or NOAC therapy during follow-up. Non-
persistence was the cumulative incidence, which was evalu-
ated by a Kaplan-Meier time-to-event analysis for each med-
ication separately [9,18].
Meta-analysis
A meta-analysis was performed to compare the persistence 
rate between NOACs and warfarin. Systematic searches were 
conducted in Medline, Embase, and Cochrane using terms 
such as warfarin, dabigatran, rivaroxaban, apixaban, non-VKA 
oral anticoagulants, non-valvular atrial fibrillation, and per-
sistence. Research studies containing persistence rate data 
of both NOACs and warfarin were included. Target study de-
signs included randomized clinical trials, prospective cohorts, 
and retrospective analysis. Studies in which time of follow-up 
was <6 months and group participants <200 were excluded.
Quality of the data was analyzed. Data of persistence rates and 
the total number of participants were extracted for meta-anal-
ysis. To minimize heterogeneity of different studies, the time 
point of follow-up at about 1 year in each study was selected 
for data extracted. Heterogeneity between studies was as-
sessed using I-squared and the P-value of the Cochrane Q test. 
Random effects model was used according to the heterogeneity 
between studies. Analyses were conducted using Revman 5.3. 
Meta-analysis results are presented as Relative Risk (RR) with 
its 95% confidence interval (CI).
Statistical analysis
Continuous variables were presented as mean ± standard de-
viation (SD), and categorical variables were presented as raw 
numbers and percentages. A time-to-event approach was used 
to analyze patient persistence to warfarin or NOACs respec-
tively. The survival distributions of persistence between the 
warfarin group and the NOACs group were compared using 
the log-rank test. Cox proportional hazards regression mod-
els were carried out to determine the association between 
OAC categories (warfarin or NOAC) and non-persistence, with 
adjustment for age, gender, education status, type of AF, co-
morbid diseases, and medications (all covariates with P<0.2 in 
the univariate models). For the analysis of predictors of war-
farin and NOACs non-persistence, Cox proportional hazards 
regression was conducted. Variables that showed significant 
association on univariate analysis and of clinical importance 
were adjusted using multivariate Cox regression. These fac-
tors included age, gender, BMI, education status, health in-
surance coverage, outpatient clinic visit within 6 months be-
fore the last follow-up, paroxysmal or persistent AF, duration 
of AF< or ³3 years, as well as those with or without previous 
TIA, stroke or thromboembolism, congestive heart failure, hy-
pertension, diabetes, prior bleeding, peptic ulcer, or use of an-
tiplatelet drugs. Multiple imputation methods were used to 
calculate the missing covariate data in Cox proportional haz-
ard regression analysis.
All P-values tests were 2-tailed and P-values <0.05 was con-
sidered statistically significant. All analyses were conducted 
using SAS statistical software version 9.4 (SAS Institute Inc, 
Cary, NC, USA).
Results
Patients characteristics
The mean age of the 4845 patients in the warfarin group was 
67.9±10.2, similar to that of the 854 patients in the NOACs 
group (68.3±11.4). Compared to patients in the NOACs group, 
patients in the warfarin group were less likely to be male (56.7% 
versus 60.9%), older than 75 years of age (29.1% versus 34.8%), 
have paroxysmal AF (44.7% versus 51.8%), have a high level 
of education (29.4% versus 49.3%), while a higher proportion 
of patients had congestive heart failure (19.1% versus 11.9%) 
and CHA2DS2-VASc score ³2 (85.8% versus 83.0%) (Table 1).
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Treatment persistence and persistence rates
Persistence rates at 1, 2, and 3 years were 93.2%, 89.4%, and 
87.2% in the warfarin group and 88.8%, 84.3%, and 81.3% in 
the NOACs group respectively (Figure 2). The treatment per-
sistence was significantly higher for warfarin than for NOACs 
(P<0.001). Patients in the NOACs group were more likely to be 
non-persistent than those in the warfarin group [hazard ratio 
(HR) for NOACs, 1.63; 95%CI: 1.31–2.02; P<0.001].
All
N = 5699
Warfarin
N = 4845
NOAC
N = 854
Male, n/N (%)  3265/5699 (57.3)  2745/4845 (56.7)  520/854 (60.9)
Age, years 67.9±10.4 67.9±10.2 68.3±11.4
age ³75 years, n/N (%)  1706/5699 (29.9)  1409/4845 (29.1)  297/854 (34.8)
BMI, kg/m2 25.6±3.7 25.6±3.7 25.6±3.8
Drinking, n/N (%)  974/5641 (17.3)  829/4804 (17.3)  145/837 (17.3)
Smoking, n/N (%)  752/5615 (13.3)  654/4807 (13.6)  98/838 (11.7)
Completed high school, n/N (%)  1680/5170 (32.5)  1286/4371 (29.4)  394/799 (49.3)
All health insurance covered, n/N (%)  657/5634 (11.7)  541/4829 (11.2)  116/805 (14.4)
Paroxysmal AF, n/N (%)  2604/5691 (45.8)  2164/4841 (44.7)  440/850 (51.8)
Congestive heart failure, n/N (%)  1028/5699 (18.0)  926/4845 (19.1)  102/854 (11.9)
Hypertension, n/N (%)  4228/5697 (74.2)  3599/4845 (74.3)  629/852 (73.8)
Diabetes, n/N (%)  1498/5698 (26.3)  1287/4845 (26.6)  211/853 (24.7)
Stroke/TIA/Thromboembolism, n/N (%)  1266/5694 (22.2)  1096/4842 (22.6)  170/852 (20.0)
Major bleeding, n/N (%)  310/5693 (5.5)  249/4842 (4.1)  61/851 (7.2)
CHA2DS2-VASc risk score ³2, n/N (%)  4637/5431 (85.4)  3972/4630 (85.8)  665/801 (83.0)
Symptomatic AF, n/N (%)  2105/5699 (36.9)  1794/4845 (37.0)  311/854 (36.4)
Peptic ulcer, n/N (%)  179/5699 (3.1)  130/4845 (2.7)  49/854 (5.7)
Duration of AF, years 4.5±6.5 4.6±6.6 3.9±5.9
Use of antiplatelet drugs, n/N (%)  3498/5699 (61.4)  2947/4845 (60.8)  551/854 (64.5)
Number of drugs used 1.9±1.4 1.9±1.5 1.8±1.4
Table 1. Baseline characteristics.
AF – indicates atrial fibrillation; SD – standard deviation; BMI – body mass index; TIA – transient ischemic attack.
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Figure 2.  Therapy persistence with warfarin and NOAC: Kaplan-
Meier curve of time to treatment discontinuation over 
3 years. The persistence rates at 1, 2, and 3 years 
were 93.2%, 89.4%, and 87.2% in the warfarin group 
and 88.8%, 84.3%, and 81.3% in the NOAC group, 
respectively. Warfarin persistence was significantly 
higher than that of NOAC using the log-lank test 
(P<0.001).
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Of the 105 patients who discontinued NOACs, 14 patients 
(13.3%) stopped because of bleeding complications. Of the 
538 patients who discontinued warfarin, 50 patients (9.29%) 
stopped because of bleeding complications. The proportions 
of patients who stopped OACs due to bleeding events were 
not different between the 2 groups (P=0.206).
Meta-analysis of non-persistence risk of NOACs compared 
with warfarin
To summarize and review the literature about persistence 
comparison between NOACs and warfarin, we sought to con-
duct a meta-analysis. A total of 11 studies were included fi-
nally [9,13,19–26]. The outcomes showed that there was no 
significant difference of non-persistence risk between NOACs 
and warfarin (RR: 0.97, 95%CI: 0.82–1.15) (Figure 3).
Predictors of treatment non-persistence
Factors associated with higher risk of warfarin non-persis-
tence include outpatient clinic visit within 6 months before 
OACs termination [HR 3.78 (3.16–4.52)], paroxysmal AF [HR 
2.37 (1.67–3.37)], duration of AF less than 3 years [HR 1.27 
(1.07–1.52)], and history of peptic ulcer [HR 1.65 (1.09–2.51)]. 
Patients older than 75 years of age [HR 0.53 (0.35–0.79)], 
symptomatic AF [HR 0.81 (0.67–0.97)], previous TIA, stroke or 
thromboembolism [HR 0.67 (0.53–0.84)] were associated with 
lower risk of non-persistence (Table 2).
In the NOACs group, patients with higher risk of non-per-
sistence were associated with factors including outpatient 
clinic visit within 6 months before OACs termination [HR 3.93 
(2.49–6.19)] and lower education status [HR 1.56 (1.03–2.38)] 
while patients older than 75 years of age [HR 0.55 (0.34–0.88)] 
and history of congestive heart failure [HR 0.46 (0.22–0.96)] 
were associated with lower risk of non-persistence (Table 2).
Factors such as education status and no history of congestive 
heart failure were associated with non-persistence only in the 
NOACs group. While factors such as paroxysmal AF, asymp-
tomatic AF, duration of AF less than 3 years, history of peptic 
ulcer, and no previous TIA, stroke or thromboembolism were 
associated with warfarin non-persistence, they had no signif-
icant difference with regard to NOACs persistence.
Discussion
To the best of our knowledge, this study is the first to investi-
gate long-term persistence and factors associated with discon-
tinuation in newly-initiated OAC patients with non-valvular AF 
in China. The most notable finding of our study was that the 
OAC treatment persistence was significantly higher for warfa-
rin than for NOACs in China, which is generally counter-intu-
itive to our perceptions, based on data in non-Asian cohorts. 
Previous studies had proposed the need for structured educa-
tional programs to improve the persistence of OAC [27]. Our 
study suggests that warfarin and NOACs may have different 
risk factors for treatment non-persistence, and therefore, dif-
ferent strategies need to be developed to address different is-
sues affecting their treatment persistence.
Medical non-persistence is associated with adverse outcomes, 
and this will result in more healthcare costs [3]. Non-persistence 
Figure 3.  Meta-analysis results of non-persistence risk for NOACs versus warfarin.
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Warfarin NOAC
N = 538 HR (95% CI) P N = 105 HR (95% CI) P
Age class
 <75 years  390/3436 (11.35) Ref. 0.002  78/557 (14.00) Ref. 0.014
 ³75 years  148/1409 (10.50)  0.53 (0.35–0.79)  27/297 (9.09)  0.55 (0.34–0.88)
Sex 
 Male  286/2745 (10.42) Ref. 0.343  65/520 (12.50) Ref. 0.295
 Female  252/2100 (12.00)  1.09 (0.91–1.30)  40/334 (11.98)  0.80 (0.53–1.22)
BMI, kg/m2
 <28  389/3548 (10.96) Ref. 0.361  84/653 (12.86) Ref. 0.413
 ³28  124/1005 (12.34)  1.10 (0.89–1.36)  20/177 (11.30)  0.81 (0.49–1.34)
Education status
 High  146/1286 (11.35) Ref. 0.806  42/394 (10.66) Ref. 0.034
 Low  344/3085 (11.15)  0.97 (0.79–1.19)  59/405 (14.57)  1.56 (1.03–2.38)
Health insurance coverage
 Partially or none  479/4288 (11.17)  0.93 (0.70–1.23) 0.594  84/689 (12.19) Ref. 0.393
 All covered 58/541 (10.72) Ref.  15/116 (12.93)  1.29 (0.72–2.33)
Outpatient clinic visit*
 Yes  241/1009 (23.88)  3.78 (3.16–4.52) <0.001  34/130 (26.15)  3.93 (2.49–6.19) <0.001
 No  297/3836 (7.74) Ref.  71/724 (9.81) Ref.
Type of AF
 Paroxysmal AF  273/2164 (12.62)  2.37 (1.67–3.37) <0.001  60/440 (13.64)  1.21 (0.81–1.80) 0.360
 Persistent or Permanent AF  264/2677 (9.86) Ref.  44/410 (10.73) Ref.
Categorization of AF
 Symptomatic  209/1794 (11.65)  0.81 (0.67–0.97) 0.022  43/310 (13.87)  1.04 (0.68–1.58) 0.858
 Asymptomatic  329/3051 (10.78) Ref.  62/544 (11.40) Ref.
Duration of AF <3 years
 Yes  335/2790 (12.01)  1.27 (1.07–1.52) 0.008  73/555 (13.15)  1.38 (0.90–2.11) 0.144
 No  203/2055 (9.88) Ref.  32/299 (10.70) Ref.
Previous TIA/stroke/thromboembolism
 Yes  91/1096 (8.30)  0.67 (0.53–0.84) 0.001  18/170 (10.59)  0.85 (0.50–1.44) 0.536
 No  446/3746 (11.91) Ref.  87/682 (12.76) Ref.
Congestive heart failure
 Yes  91/926 (9.83)  0.83 (0.66–1.04) 0.112  8/102 (7.84)  0.46 (0.22–0.96) 0.038
 No  447/3919 (11.41) Ref.  97/752 (12.90) Ref.
Either hypertension or diabetes
 Yes  432/3827 (11.29)  0.70 (0.46–1.08) 0.107  78/664 (11.75)  0.87 (0.54–1.40) 0.564
 No  106/1018 (10.41) Ref.  27/189 (14.28) Ref.
Table 2. Main predictors of warfarin and NOAC non-persistence.
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of OAC increases the risk of ischemic stroke in AF patients [28]. 
Indeed, warfarin persistence has been well-documented in pre-
vious studies, and the non-persistence rates at 1 year ranged 
from 22% to 33% [13,29,30]. A previous study described war-
farin discontinuation rates at 1 year and 2 years as 44.4% and 
57.6% in China [31], which were much higher than rates in the 
present study; this might be because the population selected 
included patients who underwent AF radiofrequency ablation 
and these patients might stop OACs after restoring sinus rhythm.
Other recent studies have described the persistence rates 
for NOAC at 1 year ranging from 63% to 79% [22,28,32]. In 
our study, treatment persistence rates were relatively higher 
than those studies. This could possibly be explained by the 
differences in terms of patient populations, study designs, and 
definitions of persistence. Comparing persistence rates across 
studies is difficult, even those focused on the same OAC.
Persistence comparisons between NOAC and warfarin remain 
controversial. The majority of previous data published showed 
that patients taking NOACs had better persistence compared 
with VKAs [12]. However, other studies showed the opposite 
results. In the RE-LYs trial, warfarin had higher 2-year persis-
tence rates compared with dabigatran 110 mg (83.4% versus 
79.3%) [22]. Observational studies have generally been consis-
tent. For example, a recent study enrolled 7150 American AF pa-
tients treated with warfarin [N=6691 (93.6%)] and dabigatran 
[N=459 (6.4%)] between June 29, 2010 and August 09, 2011, 
and defined non-persistence as discontinuing dabigatran or 
warfarin at 6 months or 1 year for any reason, and showed 
lower persistence of dabigatran versus warfarin at 1 year, with 
persistence rates 66% versus 82% [13]. In Japan, Shiga et al. 
retrospectively studied 401 Japanese patients with NVAF who 
had newly started NOACs and 200 patients with NVAF who 
had newly started warfarin during the same period; persis-
tence rates of patients prescribed NOACs were consistently 
lower than those of patients prescribed warfarin at 3, 6, and 
12 months (85% versus 93%, 79% versus 88%, and 70% ver-
sus 82% respectively) [14].
Our results are therefore in line with these studies, showing 
a lower persistence for NOACs than for warfarin. The lower 
persistence rate of NOACs in our study might be explained by 
the higher incidence of adverse events including dyspepsia and 
hepatobiliary disorders of NOACs compared with warfarin [22], 
as well as high price and non-coverage by health insurance of 
NOACs in China. Indeed, high costs of medications often con-
tribute to non-persistence [33]. Some studies showed a signif-
icant difference of non-persistence risk between NOACs and 
warfarin. However, the meta-analysis did not show a signifi-
cant difference between them. This might be due to the het-
erogeneity between studies. Further research studies should 
be undertaken to delineate the comparison of persistence 
rate by subgroups.
Table 2 continued. Main predictors of warfarin and NOAC non-persistence.
Warfarin NOAC
N = 538 HR (95% CI) P N = 105 HR (95% CI) P
Prior bleeding
  Yes  28/249 (11.24)  1.04 (0.71–1.52) 0.853  11/61 (18.03)  1.55 (0.81–2.97) 0.186
 No  509/4593 (11.08) Ref.  94/790 (11.90) Ref.
Peptic ulcer
 Yes  23/130 (17.69)  1.65 (1.09–2.51) 0.019  4/49 (8.16)  0.55 (0.20–1.51) 0.244
 No  515/4715 (10.92) Ref.  101/805(12.54) Ref.
Use of antiplatelet drugs
 Yes  349/2947 (11.84)  1.15 (0.96–1.39) 0.124  70/555 (12.61)  0.78 (0.51–1.19) 0.245
 No  189/1898 (9.96) Ref.  35/299 (11.70) Ref.
Number of drugs used*
 ³3  214/1642 (13.03)  1.02 (0.84–1.23) 0.859  36/274 (13.14)  0.93 (0.59–1.47) 0.768
 <3  324/3203 (10.11) Ref.  69/580 (11.89) Ref.
CI – indicates confidence interval; HR – hazard ratio; BMI – body mass index; TIA – transient ischemic attack. * Within 6 months before 
following up termination.
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We subsequently identified several clinical factors significantly 
associated with warfarin discontinuation. Patients older than 
75 years of age were less likely to discontinue warfarin. Prior 
studies also found older patients were more likely to be per-
sistence [34–36]. Older patients are at high risk of stroke, and 
they might contact healthcare professionals more frequently 
and are supervised more strictly. It was interesting that pa-
tients who had been to outpatient clinic within 6 months be-
fore OACs termination were more likely to be non-persistence. 
Outpatient clinic visits were commonly associated with ad-
verse drug reactions. These patients might stop warfarin due 
to serious side effects such as intracranial hemorrhage and 
gastrointestinal bleeding [37]. Patients with a history of pep-
tic ulcer also had a lower likelihood of persistence in the war-
farin group. Bleeding risk will be higher for those with a his-
tory of peptic ulcer when treated by warfarin [38]. This risk 
worries the patients and doctors which might be reflected by 
a lower treatment persistence for warfarin.
Other predictors for the persistence of warfarin therapy included 
symptomatic AF, persistent or permanent AF, duration of AF 
³3 years, history of peptic ulcer, and previous TIA, stroke or 
thromboembolism. These factors primarily either reflected 
the severity of the AF or were associated with a higher risk of 
stroke [39,40]. Clinicians and the patients might thus pay more 
attention to the anticoagulation therapy and be less likely to 
discontinue the medication. Furthermore, patients who expe-
rienced a previous TIA, stroke or thromboembolism, or who 
have been suffering AF for a long period might be more likely 
to take care of their condition and to continue their anticoag-
ulation therapy. However, we did not find these factors asso-
ciated with NOACs persistence in our study.
Patients older than 75 years of age or who had been to an out-
patient clinic within 6 months before OACs termination had 
similar effects on NOAC persistence and warfarin. Possible 
explanations might also be similar. Patients with a history of 
congestive heart failure were associated with higher persis-
tence only for NOACs, possibly because heart failure patients 
are generally followed by cardiologists, who appreciate the 
importance of anticoagulation better than other specialists. 
Low educated status was associated with non-persistence for 
NOACs but not for warfarin, perhaps reflecting that social eco-
nomic status and affordability of the medicine is important for 
therapeutic persistence.
Limitations
This study had several limitations that should be considered. 
First, the patients in our study primarily came from the Beijing 
area, an area at a higher economic level than that of other 
areas. Therefore, the patients might not be representative of 
the entire Chinese population, especially the rural areas where 
low-income people resident. Second, discontinuation of OAC 
was calculated by self-reported time, and we did not consider 
restarting of OAC usage, which might result in lower persistence. 
Third, clinical factors such as the liver and renal function and 
international normalized ratio testing were not incorporated 
in the study because of incomplete data. Fourth, the reasons 
for discontinuation remained unclear in a majority of cases.
Conclusions
Treatment persistence of NOACs was lower than that of war-
farin amongst Chinese patients with AF. Strategies are needed 
for better management of OACs therapy.
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